Elvucitabine
From Self-sufficiency
| File:Elvucitabine.png | |
| Systematic (IUPAC) name | |
|---|---|
|
4-Amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one | |
| Identifiers | |
| CAS Number | 181785-84-2 |
| ATC code | none |
| PubChem | CID 469717 |
| Chemical data | |
| Formula | C9H10FN3O3 |
| Molar mass | 227.19 g/mol[[Script error: No such module "String".]] |
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV.
Currently, it is in Phase II clinical trials.[1]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 50px | This antiinfective drug article is a stub. You can help ssf by expanding it. |
- ↑ "AIDSmeds.com - Elvucitabine". Retrieved 2008-03-21.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Nucleoside analog reverse transcriptase inhibitors
- Pyrimidones
- Dihydrofurans
- Organofluorides
- Antiinfective agent stubs
- 2Fix
